HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Andrew C. Fiore Hendrick B. Barner Marc T. Swartz Lawrence R. McBride Gary L. Grunkemeier George C. Kaiser Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fiore, A. C. Articles by Kaiser, G. C. Search for Related Content PubMed PubMed Citation Articles by Fiore, A. C. Articles by Kaiser, G. C.

Ann Thorac Surg 1998;66:707-713
© 1998 The Society of Thoracic Surgeons

---

Original articles: Cardiovascular

Mitral valve replacement: randomized trial of St. Jude and Medtronic Hall prostheses

^a Division of Cardiothoracic Surgery and Cardiology, Saint Louis University Health Sciences Center, St. Louis, Missouri, USA

Address reprint requests to Dr Fiore, Department of Surgery, Saint Louis University Health Sciences Center, 3635 Vista at Grand Blvd, St. Louis, MO 63110-0250

Presented at the Thirty-fourth Annual Meeting of The Society of Thoracic Surgeons, New Orleans, LA, Jan 26–28, 1998.

Background. This study was designed to better define the merits of the bileaflet and tilting-disc valves.

Methods. We prospectively randomized 156 patients (mean age, 59 years) to receive either the St. Jude (n = 80) or the Medtronic Hall (n = 76) mitral valve prosthesis between September 1986 and December 1997. The two groups were not significantly different with respect to preoperative New York Heart Association class, left ventricular ejection fraction, incidence of mitral stenosis or insufficiency, extent of coronary artery disease, completeness of revascularization, or cross-clamp or bypass time.

Results. The operative mortality (11.2% versus 13.1%, St. Jude versus Medtronic Hall, respectively) and late mortality (27% versus 22%, St. Jude versus Medtronic Hall, respectively) were not significantly different. Follow-up was complete in all hospital survivors with a mean of 60.7 months (range, 1 to 133 months). The analysis of 10-year actuarial survival and freedom from valve-related events demonstrated no significant differences between the cohorts. Freedom from reoperation was higher in the St. Jude group (p < 0.01). Comparisons of patient functional status and echocardiographic hemodynamic parameters obtained at the time of follow-up demonstrated no significant differences between the two prostheses.

Conclusions. This study suggests that there is no difference between the St. Jude and Medtronic Hall prostheses with respect to late clinical performance or hemodynamic results and therefore does not support the preferential selection of either prosthesis.

This article has been cited by other articles:

				D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 593S - 629S. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, T. Absi, and S. Aranki Mitral Valve Replacement Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068. [Full Text]

				H. Machler, G. Reiter, M. Perthel, U. Reiter, P. Bergmann, M. Zink, R. Rienmuller, and J. Laas Influence of a tilting prosthetic mitral valve orientation on the left ventricular flow -- an experimental in vivo magnetic resonance imaging study Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 102 - 107. [Abstract] [Full Text] [PDF]

				D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 457S - 482S. [Abstract] [Full Text] [PDF]

				K. Bando, J. Kobayashi, M. Hirata, T. Satoh, K. Niwaya, O. Tagusari, S. Nakatani, T. Yagihara, and S. Kitamura Early and late stroke after mitral valve replacement with a mechanical prosthesis: risk factor analysis of a 24-year experience J. Thorac. Cardiovasc. Surg., August 1, 2003; 126(2): 358 - 364. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, S. Aranki, and L. H. Cohn Mechanical/Bioprosthetic Mitral Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 951 - 986. [Full Text]

				R. Moidl, P. Simon, and E. Wolner The On-X prosthetic heart valve at five years Ann. Thorac. Surg., October 1, 2002; 74(4): S1312 - 1317. [Abstract] [Full Text] [PDF]

				P. D. Stein, J. S. Alpert, H. I. Bussey, J. E. Dalen, and A. G.G. Turpie Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves Chest, January 1, 2001; 119 (2009): 220S - 227S. [Full Text] [PDF]

				S. Torregrosa, J. Gomez-Plana, F. J. Valera, J. Caffarena, J. M. Maronas, F. Garcia-Sanchez, J. Peris, R. Frias, and J. M. Caffarena Long-term clinical experience with the omnicarbon prosthetic valve Ann. Thorac. Surg., September 1, 1999; 68(3): 881 - 886. [Abstract] [Full Text] [PDF]